Cambridge Heartwear is advancing AI-powered ECG wearables with HeartSense, a reusable device combining medical-grade multi-channel ECG monitoring, adaptive AI and wireless charging. The wearable provides continuous, real-time ECG data through a mobile phone, allowing cardiac monitoring to extend beyond traditional hospital environments and into homes and community settings. Its AI-supported system is designed to help identify cardiovascular disease and stroke risk earlier, while providing clinicians with diagnostic-quality information for decision-making.
A £184 million NHS Supply Chain tender creates an opportunity to deploy HeartSense across primary and secondary care at scale. Moving cardiac diagnostics closer to patients could help reduce hospital waiting times and pressure on secondary care services while supporting earlier intervention. For Cambridge Heartwear, NHS adoption also provides significant institutional validation as the company pursues further regulatory expansion, including FDA clearance in the United States.
Image Credit: Cambridge Heartwear Limited
Why This Trend Is Growing
- AI Cardiac Wearables
- Continuous ECG monitoring paired with adaptive algorithms creates new pathways for earlier cardiovascular risk detection outside clinical settings.
- Mobile Diagnostic Platforms
- Smartphone-connected medical devices are reshaping diagnostics by making hospital-grade data accessible in homes, clinics and community care environments.
- Decentralized Preventive Care
- Shifting cardiac monitoring closer to patients signals growth potential for health systems focused on reducing wait times and enabling earlier intervention.
Industries Being Reshaped
- Digital Health
- AI-enabled remote monitoring technologies are expanding the role of software-driven care models in chronic disease detection and management.
- Medical Devices
- Reusable, wireless and diagnostic-grade wearables represent a fast-evolving category that blends regulated hardware with intelligent clinical analytics.
- Healthcare Services
- Primary and secondary care providers are gaining opportunities to redesign cardiac pathways around scalable remote diagnostics and clinician-ready data.
